Program
Esomeprazole
Also written as “esomeprazole”, “PN400” and “Esomeprazole (Nexium)”.
Its studies are mostly in Gastroesophageal Reflux · Stomach Ulcer · Heartburn · Esophagitis, Peptic · Gastrointestinal Diseases, led by 15 companies.
Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| AstraZeneca | 920 open or running | phase 4since Sep 12, 2005 | Mar 16, 2004 | none ahead |
| Hanmi Pharmaceutical | 50 open or running | phase 3since Sep 4, 2019 | Dec 8, 2017 | none ahead |
| Aralez Pharmaceuticals | 40 open or running | phase 1since Jan 11, 2008 | Jan 11, 2008 | none ahead |
| Chong Kun Dang Pharmaceutical | 30 open or running | phase 1since Feb 6, 2018 | Feb 6, 2018 | none ahead |
| Pfizer | 30 open or running | phase 4since Jan 21, 2016 | Feb 25, 2012 | none ahead |
| Takeda | 30 open or running | phase 2since Apr 14, 2016 | Jul 16, 2009 | none ahead |
| Torrent Pharmaceuticals | 30 open or running | phase 1since Nov 9, 2015 | Nov 9, 2015 | none ahead |
| EMS | 20 open or running | phase 4since Sep 2, 2015 | Sep 2, 2015 | none ahead |
| Elpen Pharmaceutical | 10 open or running | phase 4since Nov 7, 2016 | Nov 7, 2016 | none ahead |
| Eurofarma Laboratorios | 10 open or running | phase 3since Oct 31, 2011 | Oct 31, 2011 | none ahead |
| Genuine Research Center, Egypt | 10 open or running | phase 1since Sep 6, 2021 | Sep 6, 2021 | none ahead |
| HALEON | 10 open or running | phase 1since Feb 22, 2022 | Feb 22, 2022 | none ahead |
| Johnson & Johnson | 10 open or running | phase 4since Apr 20, 2007 | Apr 20, 2007 | none ahead |
| Joincare Pharmaceutical Group Industry | 11 open or running | phase 3since Feb 7, 2025 | Feb 7, 2025 | none ahead |
| SD Biosensor | 10 open or running | phase 4since Jan 19, 2009 | Jan 19, 2009 | none ahead |
Also a collaborator on its studies: iqvia-rds-inc, laboratory-corporation-of-america, medidata-solutions, thermo-fisher-scientific-inc, ciscrp, arvinas-estrogen-receptor-inc, parexel and quintiles-inc.
How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
Before these, 46 studies since May 8, 2008.
- Dec 8, 2017Hanmi Pharmaceutical's first study: phase 1 study in HealthyNew to Hanmi PharmaceuticalHanmi Pharmaceutical · NCT03372850 · 96 enrolled · Korea, Republic of
- Feb 6, 2018Chong Kun Dang Pharmaceutical's first study: phase 1 study in Gastroesophageal RefluxNew to Chong Kun Dang PharmaceuticalChong Kun Dang Pharmaceutical · NCT03444402 · 18 enrolled · Korea, Republic of
- Apr 5, 2018Phase 3 study in Esophagitis, PepticAstraZeneca · NCT03553563 · 50 enrolled · Japan
- Jun 1, 2018Phase 1 study in Gastroesophageal RefluxChong Kun Dang Pharmaceutical · NCT03558425 · 41 enrolled · Korea, Republic of
- Mar 18, 2019Phase 1 study in Heathy VolunteerHanmi Pharmaceutical · NCT03882112 · 24 enrolled · Korea, Republic of
- Sep 4, 2019Phase 3 study in Erosive Gastroesophageal Reflux DiseaseHanmi Pharmaceutical · NCT04080726 · 213 enrolled · Korea, Republic of
- Dec 17, 2019Phase 1 study in Healthy VolunteerHanmi Pharmaceutical · NCT04204629 · 25 enrolled · Korea, Republic of
- Mar 26, 2020Phase 3 study in Non-erosive Gastroesphageal Reflux DiseaseHanmi Pharmaceutical · NCT04325620 · 208 enrolled · Korea, Republic of
- Jan 7, 2021Phase 1 study in Gastroesophageal RefluxChong Kun Dang Pharmaceutical · NCT04703374 · 48 enrolled · Korea, Republic of
- Sep 6, 2021Genuine Research Center, Egypt's first study: phase 1 study in HealthyNew to Genuine Research Center, EgyptGenuine Research Center, Egypt · NCT05038969 · 30 enrolled · Egypt
- Jan 31, 2022Phase 3 study in Gastroesophageal RefluxAstraZeneca · NCT05267613 · 53 enrolled · United States, Argentina, Australia and more
- Feb 22, 2022HALEON's first study: phase 1 study in Gastrointestinal DiseasesNew to HALEONHALEON · NCT05265247 · 61 enrolled · Canada
- Feb 16, 2024Phase 1 study in HealthyPfizer · NCT06275841 · 12 enrolled · United States
- Feb 7, 2025Joincare Pharmaceutical Group Industry's first study: phase 3 study in Esophagitis, PepticNew to Joincare Pharmaceutical Group IndustryJoincare Pharmaceutical Group Industry · NCT06850480 · 356 planned · China
TargetBeta
“Potassium-transporting ATPase inhibitor; Potassium-transporting ATPase inhibitor; Potassium-transporting ATPase inhibitor”ChEMBL 37, by rule
Other programs on the same two targets
| Program | Company | Furthest phase | Studies |
|---|---|---|---|
| Rabeprazolerule | Eisai | phase 4 | 66 |
| Omeprazolerule | AstraZeneca | phase 4 | 56 |
| tegoprazanrule | HK inno.N | phase 4 | 48 |
| vonoprazanrule | Takeda | phase 4 | 48 |
| fexuprazanrule | Daewoong Pharmaceutical | phase 4 | 29 |
Studies
The newest 60 of 122 led by companies developing it. Each opens its study page. Every study on its drug page →
| Study | Phase | Status | Led by | Primary completion | Size |
|---|---|---|---|---|---|
| NCT06850480Esophagitis, Peptic · China | 3 | Recruiting | Joincare Pharmaceutical Group Industry | Apr 15, 2025 | 356 |
| NCT06275841Healthy · United States | 1 | Completed | Pfizer | May 3, 2024 | 12 |
| NCT05265247Gastrointestinal Diseases · Canada | 1 | Completed | HALEON | Jun 2, 2022 | 61 |
| NCT05267613Gastroesophageal Reflux · United States, Argentina, Australia and more | 3 | Completed | AstraZeneca | Aug 10, 2026 | 53 |
| NCT05038969Healthy · Egypt | 1 | Completed | Genuine Research Center, Egypt | Apr 1, 2021 | 30 |
| NCT04703374Gastroesophageal Reflux · Korea, Republic of | 1 | UNKNOWN | Chong Kun Dang Pharmaceutical | Sep 2021 | 48 |
| NCT04325620Non-erosive Gastroesphageal Reflux Disease · Korea, Republic of | 3 | Completed | Hanmi Pharmaceutical | Aug 3, 2020 | 208 |
| NCT04204629Healthy Volunteer · Korea, Republic of | 1 | Completed | Hanmi Pharmaceutical | Feb 20, 2020 | 25 |
| NCT04080726Erosive Gastroesophageal Reflux Disease · Korea, Republic of | 3 | Completed | Hanmi Pharmaceutical | Dec 3, 2019 | 213 |
| NCT03882112Heathy Volunteer · Korea, Republic of | 1 | Completed | Hanmi Pharmaceutical | Aug 28, 2019 | 24 |
| NCT03558425Gastroesophageal Reflux · Korea, Republic of | 1 | Completed | Chong Kun Dang Pharmaceutical | Sep 14, 2018 | 41 |
| NCT03553563Esophagitis, Peptic · Japan | 3 | Completed | AstraZeneca | Dec 27, 2022 | 50 |
| NCT03444402Gastroesophageal Reflux · Korea, Republic of | 1 | Completed | Chong Kun Dang Pharmaceutical | May 4, 2018 | 18 |
| NCT03372850Healthy · Korea, Republic of | 1 | UNKNOWN | Hanmi Pharmaceutical | Jun 15, 2018 | 96 |
| NCT03083639Healthy Participants · United States | 1 | Completed | Takeda | May 13, 2017 | 52 |
| NCT02959255Helicobacter Pylori Infection · Greece | 4 | Completed | Elpen Pharmaceutical | Dec 30, 2017 | 364 |
| NCT02743949Gastroesophageal Reflux · Belgium, Bulgaria, Czechia and more | 2 | Completed | Takeda | Oct 5, 2018 | 256 |
| NCT02680132Healthy | 1 | Completed | Torrent Pharmaceuticals | May 2011 | 56 |
| NCT02680119Healthy | 1 | Completed | Torrent Pharmaceuticals | May 2011 | 56 |
| NCT02708355Heartburn · United States | 4 | Completed | Pfizer | Apr 2016 | 55 |
| NCT02670642Gastroesophageal Reflux · Austria, France, Germany and more | 3 | Completed | AstraZeneca | Nov 2002 | 877 |
| NCT02624544Psoriasis | 4 | Withdrawn | EMS | Jan 2016 | 0 |
| NCT02659683Healthy Subjects | 1 | Completed | Torrent Pharmaceuticals | May 2011 | 54 |
| NCT02552641Helicobacter Pylori Infection · Brazil | 4 | Withdrawn | EMS | Feb 2016 | 0 |
| NCT02153398Stomach Ulcer · Japan | 3 | Completed | AstraZeneca | Apr 2016 | 55 |
| NCT02157376Gastrointestinal Hemorrhage · China | 3 | Completed | AstraZeneca | Feb 2016 | 343 |
| NCT01964131Stomach Ulcer · Japan | 1 | Completed | AstraZeneca | Dec 2013 | 34 |
| NCT01757275Peptic Ulcer Hemorrhage · China | 3 | Completed | AstraZeneca | Dec 2014 | 239 |
| NCT01669811Esophagitis, Peptic · Japan | 3 | Completed | AstraZeneca | May 2014 | 1,398 |
| NCT01595425Bioequivalence Study · Japan | 1 | Completed | AstraZeneca | Jun 2012 | 71 |
| NCT01549574Healthy · Belgium | 1 | Completed | Pfizer | May 2012 | 16 |
| NCT01494402Bioequivalence Study · Japan | 1 | Completed | AstraZeneca | Mar 2012 | 77 |
| NCT01471925Gastroesophageal Reflux · Brazil | 3 | Withdrawn | Eurofarma Laboratorios | 0 | |
| NCT01397084Gastroesophageal Reflux | 4 | Completed | AstraZeneca | Jan 2012 | 107 |
| NCT01370538Heartburn · United States | 3 | Completed | AstraZeneca | Oct 2011 | 341 |
| NCT01370525Heartburn · United States | 3 | Completed | AstraZeneca | Oct 2011 | 340 |
| NCT01358383Arthritis, Juvenile · United States | 1 | Completed | AstraZeneca | Jun 2011 | 28 |
| NCT01249651Heartburn · China | 4 | Completed | AstraZeneca | Jun 2011 | 101 |
| NCT01210339Cardiovascular Diseases · Sweden | 1 | Completed | AstraZeneca | Aug 2011 | 58 |
| NCT01199328Peptic Ulcer · United States | 1 | Completed | AstraZeneca | Nov 2010 | 34 |
| NCT01163630Effect of Food · United States | 1 | Completed | AstraZeneca | Sep 2010 | 24 |
| NCT01159145Pharmacodynamics Study · Japan | 1 | Completed | AstraZeneca | Sep 2010 | 42 |
| NCT01119768Non-Erosive Reflux Disease · China | 4 | Completed | AstraZeneca | Jun 2011 | 305 |
| NCT01094483Platelet Inhibition · United States | 1 | Completed | AstraZeneca | May 2010 | 40 |
| NCT01069939Stomach Ulcer · Japan, Korea, Republic of, Taiwan | 3 | Completed | AstraZeneca | Nov 2011 | 427 |
| NCT01015729Peptic Ulcer · Canada | 1 | Terminated | AstraZeneca | 30 | |
| NCT00998075Peptic Ulcer · Canada | 1 | Completed | AstraZeneca | Dec 2009 | 138 |
| NCT00992381Healthy · Australia | 1 | Completed | AstraZeneca | 24 | |
| NCT00942175Stomach Ulcer · United States | 1 | Completed | Takeda | Jun 2010 | 160 |
| NCT00930215Healthy · Japan | 1 | Completed | AstraZeneca | 48 | |
| NCT00907400Healthy · Sweden | 1 | Completed | AstraZeneca | Sep 2009 | 48 |
| NCT00825630Helicobacter Pylori Infection · Israel | 4 | Completed | SD Biosensor | Nov 2009 | 123 |
| NCT00761501Healthy Volunteer · Sweden | 1 | Completed | AstraZeneca | Dec 2008 | 38 |
| NCT00734097Gastroesophageal Reflux · Argentina, Chile, Colombia and more | 4 | Completed | AstraZeneca | Oct 2008 | 314 |
| NCT00692055Arthritis · United States | 1 | Completed | Aralez Pharmaceuticals | Jul 2008 | 30 |
| NCT00688428Ulcer | 1 | Completed | AstraZeneca | Apr 2008 | 84 |
| NCT00687245Gastroesophageal Reflux | 1 | Completed | AstraZeneca | May 2008 | 40 |
| NCT00684190Gastroesophageal Reflux · Sweden | 1 | Completed | AstraZeneca | Jun 2008 | 30 |
| NCT00676442Arthritis · United States | 1 | Completed | Aralez Pharmaceuticals | Jun 2008 | 24 |
| NCT00676117Healthy · Japan | 1 | Completed | AstraZeneca | Jul 2008 | 30 |
How it is read
Names in the registry
- “Esomeprazole”, 72 entries
- “esomeprazole”, 8 entries
- “PN400”, 8 entries
- “Esomeprazole (Nexium)”, 3 entries
- “HIP1601”, 3 entries
Codes read as this program: D961H, D026.
Conditions, from the studies’ own filings
- Gastroesophageal Reflux, 40 studies
- Stomach Ulcer, 13 studies
- Heartburn, 9 studies
- Esophagitis, Peptic, 6 studies
- Gastrointestinal Diseases, 3 studies
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.